The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population
Azan Ijaz, Ghulam Mohyudin · 2026
Read The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population by Azan Ijaz, Ghulam Mohyudin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13333292.txt.
Description
Azan Ijaz and Ghulam Mohyudin wrote a 2026 letter to the editor questioning how far the safety results for the Alzheimer's drug donanemab can be stretched. A recent analysis of the TRAILBLAZER-ALZ 2 trial reported a safety profile in the population eligible under European rules.
The letter notes that this eligible group excluded everyone on blood thinners, a rule that lowers the rate of bleeding-type imaging side effects. Atrial fibrillation, the main reason older adults take such drugs, is common alongside dementia. In a Finnish cohort of over 70,000 people with Alzheimer's, about 23 percent were on oral anticoagulants at diagnosis. Removing them, the writers argue, creates a lower-risk group than clinics actually treat, and the other two exclusions, surface iron deposits and uncontrolled blood pressure, affect far fewer people. They urge readers to treat the reassuring safety figures as products of selection, not proof of better real-world tolerability.
Catalog record
| CREATOR | Azan Ijaz, Ghulam Mohyudin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5150 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |